Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06136351
PHASE2

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Sponsor: Ruijin Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy and safety of Zanubrutinib given in combination with bendamustine and rituximab in (elderly or TP53 alterations or chemotherapy intolerance) patients with newly diagnosed mantle cell lymphoma.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

23

Start Date

2023-11-15

Completion Date

2027-11-01

Last Updated

2023-11-29

Healthy Volunteers

No

Interventions

DRUG

Zanubrutinib

160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up

DRUG

Rituximab

375 mg/m\^2 ivgtt, D0 of each 28-day cycle

DRUG

Bendamustin

90mg/m\^2 ivgtt, D0 of each 28-day cycle

Locations (1)

Ruijin Hospital

Shanghai, Shanghai Municipality, China